Peter Moldt

Director/Board Member at

Cardeas Pharma Corp.

67 year

23 connections

Health Technology

Finance

Consumer Services

Profile

Peter Moldt was the founder of 7TM A, founded in 2000, where the title held was Senior Executive Vice President from 2000 to 2009.
Dr. Moldt was the founder of Curalogic AS, founded in 2004, where the title held was Chief Executive Officer from 2004 to 2009.
Dr. Moldt is currently Director at Cardeas Pharma Corp.
Dr. Moldt is currently Director at ViewPoint Therapeutics, Inc. since 2018.
Former jobs include Chairman at Allakos, Inc.; Chairman at Bolt Biotherapeutics, Inc. from 2016 to 2021; Non-Executive Director at Biotica Technology Ltd.; Director at Cytochroma, Inc.; Director at Thesan Pharmaceuticals, Inc.; Independent Director at Corvus Pharmaceuticals, Inc. from 2015 to 2019; Director-Drug Development at NTG Nordic Transport Group A; Director at Neurokey A; Director at Hemofocus ApS; Director at Strategic Partners A; Director at Arch Oncology, Inc.; Director at ESCAPE Bio, Inc.; Director at Spruce Biosciences, Inc.; Independent Director at Aligos Therapeutics, Inc.; Director at Outpost Medicine, Inc.; Director at Avalyn Pharma, Inc.; Partner at Novo Holdings A from 2009 to 2012; Partner at Novo Ventures (US), Inc. from 2012 to 2024; Partner at Novo Ventures 1 A. Education includes a doctorate from Yale University and a doctorate from Danmarks Farmaceutiske Universitet.

Peter Moldt active positions

Companies	Position	Start
Cardeas Pharma Corp. Cardeas Pharma Corp. Pharmaceuticals: MajorHealth Technology Provides drugs for the prevention of ventilator associated pneumonia	Director/Board Member	-
Viewpoint Therapeutics, Inc. Viewpoint Therapeutics, Inc. BiotechnologyHealth Technology Develops non-surgical treatments for eye diseases	Director/Board Member	2018-03-04

All active positions of Peter Moldt

Former positions of Peter Moldt

Companies	Position	End
Novo Ventures (US), Inc. Novo Ventures (US), Inc. Investment ManagersFinance Novo Ventures US invests venture capital in biotechnology and life science companies throughout the US and Europe. Their typical investments are as equity ranging from 1 to 15 million Euro. The firm may invest at any stage of development of a business idea - from seed capital over private placements to IPOs and public companies and they may invest in any part of the world.	Private Equity Investor	2024-01-30
BOLT BIOTHERAPEUTICS, INC.	Chairman	2021-11-14
CORVUS PHARMACEUTICALS, INC.	Director/Board Member	2019-01-27
Novo Holdings A/S (Denmark) Novo Holdings A/S (Denmark) Investment ManagersFinance Functions as an alternative investment manager	Corporate Officer/Principal	2012-04-30
Cytochroma, Inc. Cytochroma, Inc. Pharmaceuticals: MajorHealth Technology Develops and markets prescription products for the prevention of vitamin D insufficiency	Director/Board Member	2012-02-13

See the detail of Peter Moldt's experience

Training of Peter Moldt

Experiences
Positions held

Active

Inactive

Listed companies

Private companies

See the detail of Peter Moldt's experience

Connections

1st degree connections

1st degree companies

Male

Female

Members of the board

Executives

See the personal network

Linked companies

Private companies	25
Biotica Technology Ltd. Biotica Technology Ltd. Pharmaceuticals: MajorHealth Technology Develops and manufactures pharmaceuticals	Health Technology
Cytochroma, Inc. Cytochroma, Inc. Pharmaceuticals: MajorHealth Technology Develops and markets prescription products for the prevention of vitamin D insufficiency	Health Technology
Cardeas Pharma Corp. Cardeas Pharma Corp. Pharmaceuticals: MajorHealth Technology Provides drugs for the prevention of ventilator associated pneumonia	Health Technology
Thesan Pharmaceuticals, Inc. Thesan Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Develops and produces novel therapeutics for skin disorders	Health Technology
Avalyn Pharma Inc. Avalyn Pharma Inc. Pharmaceuticals: MajorHealth Technology Operates as a clinical-stage biopharmaceutical company that develops inhaled therapies to treat rare respiratory & interstitial lung diseases	Health Technology
Corvus Pharmaceuticals, Inc. Corvus Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Provides anticancer immuno-oncology drugs	Health Technology
NTG Nordic Transport Group A/S NTG Nordic Transport Group A/S TruckingTransportation Transports goods through truck, ship and aircraft	Transportation
Novo Holdings A/S (Denmark) Novo Holdings A/S (Denmark) Investment ManagersFinance Functions as an alternative investment manager	Finance
Yale University Yale University Other Consumer ServicesConsumer Services Functions as a College/University	Consumer Services
Danmarks Farmaceutiske Universitet Danmarks Farmaceutiske Universitet Other Consumer ServicesConsumer Services Functions as a College/University	Consumer Services
7TM A/S 7TM A/S BiotechnologyHealth Technology Operates as a biotech company that discovers and develops drugs	Health Technology
Curalogic AS Curalogic AS Pharmaceuticals: MajorHealth Technology Developes pharmaceuticals	Health Technology
Novo Ventures 1 A/S Novo Ventures 1 A/S Investment ManagersFinance Novo Ventures invests in companies located in Europe, the United States and Asia. The firm targets companies operating in the fields of health technology, health services, biotechnology and medical specialties sectors. It provides financing for early stage capital requirements.	Finance
Neurokey A/S Neurokey A/S Pharmaceuticals: MajorHealth Technology Develops drugs for the critical care field	Health Technology
Hemofocus ApS Hemofocus ApS Medical SpecialtiesHealth Technology Provides anticoagulant products	Health Technology
Strategic Partners A/S Strategic Partners A/S Pharmaceuticals: MajorHealth Technology Provides therapeutic treatment of of diseases caused by defects in the function and metabolism of proteins	Health Technology
Arch Oncology, Inc. Arch Oncology, Inc. Pharmaceuticals: MajorHealth Technology Operates as a clinical-stage immuno-oncology company that develops biologic therapies for treatment of patients with tumors and hematologic malignancies	Health Technology
Novo Ventures (US), Inc. Novo Ventures (US), Inc. Investment ManagersFinance Novo Ventures US invests venture capital in biotechnology and life science companies throughout the US and Europe. Their typical investments are as equity ranging from 1 to 15 million Euro. The firm may invest at any stage of development of a business idea - from seed capital over private placements to IPOs and public companies and they may invest in any part of the world.	Finance
Allakos, Inc. Allakos, Inc. Pharmaceuticals: MajorHealth Technology Operates as a clinical stage biotechnology company that develops innovative therapeutics which target immunomodulatory receptors for the treatment of allergic, inflammatory and proliferative diseases	Health Technology
Bolt Biotherapeutics, Inc. Bolt Biotherapeutics, Inc. Pharmaceuticals: MajorHealth Technology Operates as a clinical-stage immuno-oncology company	Health Technology
Viewpoint Therapeutics, Inc. Viewpoint Therapeutics, Inc. BiotechnologyHealth Technology Develops non-surgical treatments for eye diseases	Health Technology
Outpost Medicine, Inc. Outpost Medicine, Inc. Pharmaceuticals: MajorHealth Technology Engages in drug development activities	Health Technology
ESCAPE Bio, Inc. ESCAPE Bio, Inc. BiotechnologyHealth Technology Develops small molecule therapeutics against genetic targets for neurodegenerative disease	Health Technology
Spruce Biosciences, Inc. Spruce Biosciences, Inc. BiotechnologyHealth Technology Operates as biopharmaceutical company which develops novel therapies for endocrine diseases	Health Technology
Aligos Therapeutics, Inc. Aligos Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Develops targeted, curative therapies for hepatologic diseases and viral infections	Health Technology